Compounded semaglutide has become widely discussed as an alternative to brand-name GLP-1 medications — particularly as Ozempic and Wegovy supply constraints made access difficult for many patients. But the terminology around compounded medications is frequently misused, and some descriptions of compounded semaglutide are not just inaccurate — they are specifically prohibited by FDA guidance.
This guide explains what compounded semaglutide actually is, the legal framework that governs it, how it differs from Ozempic and Wegovy, and what physician supervision means for safety and outcomes. If you are evaluating Vitality's medical weight loss program, this is the background you need.
What Is Drug Compounding?
Drug compounding is the preparation of a customized medication by a licensed pharmacist for a specific patient, pursuant to a valid physician prescription. The FDA defines compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act (FD&C Act), which governs traditional patient-specific compounding pharmacies.
Under 503A compounding:
- A licensed physician must write a prescription for a specific, identified patient
- A licensed compounding pharmacy prepares the medication to meet that patient's specific clinical needs
- The compounded medication is not manufactured in bulk; it is prepared for individual patients
- The pharmacy must comply with applicable state pharmacy board regulations and USP compounding standards
Compounding has a legitimate role in medicine when a patient needs a specific dose, formulation, or combination that is not available in a commercially manufactured product. Compounded medications are not FDA-approved, but they are legally prescribed and prepared when specific criteria are met.
How Compounded Semaglutide Differs from Ozempic and Wegovy
Semaglutide is the active ingredient in two FDA-approved drugs: Ozempic (approved for the management of type 2 diabetes, doses 0.5 mg–2 mg weekly) and Wegovy (approved for chronic weight management in adults with obesity or overweight with comorbidities, 2.4 mg weekly).
Compounded semaglutide is a distinct formulation — not a generic and not FDA-approved. It is prepared by a licensed 503A compounding pharmacy under a physician's prescription for a specific patient. The correct framing is this:
Semaglutide is the active ingredient in both Ozempic (approved for type 2 diabetes) and Wegovy (approved for weight management). Compounded semaglutide is a distinct formulation — not a generic and not FDA-approved. It is prepared by a licensed 503A compounding pharmacy under a physician's prescription for a specific patient.
This distinction matters legally and clinically. In September 2025, the FDA issued warning letters to medical practices that described compounded semaglutide as the “same as Ozempic” or used similar language — language the FDA considers false or misleading. Vitality does not use this language, and does not describe compounded semaglutide as a generic.
Is Compounded Semaglutide Legal?
503A patient-specific compounding is legal when prescribed by a licensed physician for a specific patient. Semaglutide appeared on the FDA's drug shortage list, which at that time expanded access to compounded semaglutide under additional provisions of compounding law. The shortage was officially removed in February 2025.
Following the shortage removal, the regulatory landscape for compounded semaglutide changed:
- 503A patient-specific compounding (individual prescriptions from licensed physicians for specific patients) remains a legal prescription pathway
- 503B bulk compounding (outsourcing facilities producing large-scale batches of compounded semaglutide) is under increased FDA scrutiny and enforcement following the shortage removal
Vitality prescribes compounded semaglutide through licensed 503A compounding pharmacy partners. The legal status of compounded medications can change — patients should confirm current status with their physician.
Is Compounded Semaglutide Safe?
The safety of compounded semaglutide depends on two things: the quality of the compounding pharmacy and the presence of physician oversight.
When compounded semaglutide is prepared by a licensed, USP-compliant 503A pharmacy using appropriate pharmaceutical-grade semaglutide and correct excipients, the safety profile is comparable to the brand-name formulations. The dose titration protocols, monitoring requirements, and contraindications are the same.
The safety risks arise when compounded semaglutide is obtained from unverified sources:
- Incorrect concentration or dosing (leading to overdose or underdose)
- Contamination from non-sterile compounding environments
- Use of inappropriate semaglutide salts or excipients
- No physician oversight — no labs, no monitoring, no dose titration
Vitality uses vetted 503A pharmacy partners and requires physician evaluation before any prescription is written. The prescription is never issued without a review of labs and health history.
Why Patients Choose Compounded Semaglutide
The primary reasons patients opt for compounded semaglutide over brand-name formulations:
- Cost differences — brand-name Wegovy has a list price exceeding $1,349 per month. Insurance coverage for weight management medications is inconsistent. Compounded semaglutide through 503A pharmacies is typically more affordable, making physician-supervised treatment accessible to patients who would otherwise not have access
- Access — brand-name supply constraints have made Ozempic and Wegovy difficult to obtain consistently in some markets; 503A compounding offers an alternative supply pathway
- Dose flexibility — compounded formulations can be prepared in specific doses that allow for more flexible titration than standard pre-filled pens, which is useful for patients who need a slower escalation
The Vitality Approach: Physician-Prescribed Only
Vitality prescribes semaglutide — both compounded 503A formulations and brand-name where appropriate — exclusively through physician evaluation. Dr. Jaqua reviews labs before prescribing, including fasting glucose, HbA1c, thyroid function, and basic metabolic panel. No prescription is issued without this evaluation.
The treatment protocol follows the same titration schedule regardless of whether the formulation is compounded or brand-name: starting at the lowest effective dose and increasing based on tolerance and response. Regular check-ins are built into the program — not optional follow-ups.
For more information about Vitality's semaglutide program, including candidacy criteria and what to expect at your first appointment, see our semaglutide service page or visit our medical weight loss program page. Book a free consultation to review your labs with Dr. Jaqua and determine whether semaglutide is the right fit for your goals.
Frequently Asked Questions
Is compounded semaglutide FDA-approved?
No. Compounded semaglutide is not FDA-approved. FDA approval applies to specific manufactured drug products — in this case, Ozempic (approved for type 2 diabetes management) and Wegovy (approved for chronic weight management). Compounded semaglutide is a patient-specific formulation prepared by a licensed 503A compounding pharmacy under a physician's prescription. It is a legally prescribed compounded medication, not a generic or an approved drug product.
Can I get compounded semaglutide without a doctor?
No. Compounded semaglutide requires a physician's prescription. Under 503A compounding law, a licensed compounding pharmacy may only prepare a compounded formulation for a specific patient when a valid physician prescription is present. Any service offering compounded semaglutide without a physician evaluation and prescription is operating outside the legal framework — and represents a safety risk.
Is compounded semaglutide the same as Ozempic?
No. Compounded semaglutide is not the same product as Ozempic or Wegovy. It is a distinct compounded formulation prepared under physician prescription at a licensed 503A pharmacy. It is not FDA-approved and is not described as a generic. Semaglutide is the active ingredient in both Ozempic and Wegovy — but compounded semaglutide is prepared by a compounding pharmacy as a patient-specific formulation, which is a different product under a different legal and regulatory framework.
How do I know if compounded semaglutide is safe?
Safety depends primarily on two factors: the quality of the compounding pharmacy and the presence of physician oversight. Vitality uses vetted 503A licensed pharmacy partners that meet pharmacy board and USP compounding standards. In addition, Dr. Jaqua reviews labs before prescribing, establishes a titration schedule, and monitors patient response through regular check-ins. Compounded semaglutide obtained from unverified sources — without physician involvement — carries real risks including incorrect dosing, contamination, and no monitoring for adverse effects.
References
- U.S. Food & Drug Administration. “Compounding and the FDA: Questions and Answers.” FDA.gov. Section 503A of the FD&C Act.
- FDA Warning Letters to compounding facilities regarding semaglutide marketing claims. September 2025.
- FDA Drug Shortage Database — semaglutide shortage status removed February 2025.